Novel antagonists for α1-adrenoceptor subtypes

Expert Opinion on Therapeutic Patents

Volumn 14, Issue 5, 2004, Pages 619-637

  Romeo, Giuseppe ^a   Materia, Luisa ^a   Salerno, Loredana ^a   Russo, Filippo ^a   Minneman, Kenneth P ^b  

^a UNIVERSITY OF CATANIA   (Italy)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Benign prostatic hypertrophy; Hypertension; 1 adrenergic receptor; 1 adrenoceptor antagonist; 1 adrenoceptor subtypes

Indexed keywords

1 PHENYLPIPERAZINE DERIVATIVE; 1,2,3,4 TETRAHYDROPYRIMIDINE DERIVATIVE; 1,4 DIHYDRO 2,6 DIMETHYL 4 (4 NITROPHENYL) 3,5 PYRIDINEDICARBOXYLIC ACID [3 (4,4 DIPHENYL 1 PIPERIDINYL)PROPYL]AMIDE METHYL ESTER; 1,4 DIHYDROPYRIDINE; 2 OXAZOLIDINONE DERIVATIVE; 2 [[2 (2,6 DIMETHOXYPHENOXY)ETHYL]AMINOMETHYL] 1,4 BENZODIOXAN; 4 AMINO 2 [4 BENZYLOXYCARBONYL 3 [(TERT BUTYLAMINO)CARBONYL] 1 PIPERAZINYL] 6,7 DIMETHOXYQUINAZOLINE; 4 PHENYLPIPERIDINE DERIVATIVE; 8 [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] 8 AZASPIRO[4.5]DECANE 7,9 DIONE; A 123189; A 315456; ABT 866; ALFUZOSIN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; DOXAZOSIN; FIDUXOSIN; IMIDAZOLE DERIVATIVE; MEMBRANE RECEPTOR; NIGULDIPINE; NITRIC OXIDE; PIPERIDINE DERIVATIVE; PRAZOSIN; QUINAZOLINE DERIVATIVE; RECEPTOR SUBTYPE; SNAP 7915; SNAP 8719; TAMSULOSIN; TERAZOSIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BLADDER OBSTRUCTION; CARDIOVASCULAR SYSTEM; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG RESEARCH; DRUG SELECTIVITY; DRUG STRUCTURE; EJACULATION DISORDER; HUMAN; HYPERTENSION; MOLECULAR CLONING; NONHUMAN; NOSE CONGESTION; ORTHOSTATIC HYPOTENSION; PATENT; PROSTATE HYPERTROPHY; PROTEIN ANALYSIS; PROTEIN FAMILY; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; TACHYCARDIA;

EID: 2642572682     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.14.5.619     Document Type: Review

References (75)

1. PUPO AS, MINNEMAN KP: Adrenergic pharmacology: focus on the central nervous system. CNS Spectrums (2001) 6:656-662.
2. 1-adrenergic receptors: new insights and directions. J. Pharmacol. Exp. Ther. (2001) 298:403H410.
3. 1-Adrenoceptor subtypes. Eur. J. Pharmacol. (1999) 375:261-276.
4. 1-adrenoceptors: consensus update. Pharmacol. Rev. (1995) 47:267-270.
5. HALL RA, PREMONT RT, LEFKOWITZ RJ: Heptahelical receptor signaling: beyond the G protein paradigm. J. Cell. Biol. (1999) 145:927-932.
6. 1-adrenoceptor isoforms. FEBS Lett. (1998) 422:279-283.
7. 1A-adrenoceptors. Biochem. J. (1999) 343:231-239.
8. 1L-adrenoceptor pharmacology in functional studies. Eur. J. Pharmacol, (1999) 370:337-343.
9. 1-adrenoceptors in human prostate: implications for adrenoceptor classification. Mol. Pharmacol (1996) 49-209-215.
10. STAM WB, VAN DER GRAAF PH, SAXENA PR: Analysis of alpha 1L-adrenoceptor pharmacology in rat small mesenteric artery. Br. J. Pharmacol. (1999) 127:661-670.
11. 1-adrenoceptor classification. Br. J. Pharmacol. (1997) 121:1127-1135.
12. 2-adrenoceptor subtypes: therapeutic implications. Exp. Opin. Invest. Drugs (1997) 6:367-387.
13. '1-adrenoreceptor antagonist, in human prostate and vasculature. J. Urol. (2000) 164:578-583.
14. 1-Adrenergic receptor subtypes: non-identical triplets with different dancing partners? Life Sci. (2003) 74:411-418.
15. 2-adrenoceptor subtypes: therapeutic implications. Exp. Opin. Invest. Drugs (1997) 6:367-387.
16. h is subtype specific and independent of its transglutaminase activity. J. Biol. Chem. (1996) 271:32385-32391.
17. h/tissue transglutaminase II. J. Biol. Chem. (2001) 276:20673-20678.
18. 1-adrenoceptors in rat blood vessels. Eur. J. Pharmacol. (1990) 190:97-104.
19. C is expressed in resistance arteries and is required to maintain arterial blood pressure. Proc. Natl. Acad. Sci. USA (2002) 99:9474-9479.
20. 1B-adrenergic receptor. Proc. Natl. Acad. Sci. USA (1997) 94:11589-11594.
21. 1D-adrenergic receptor directly regulates arterial blood pressure via vasoconstricrion. J. Clin. Invest. (2002) 109:765-775.
22. 1B-adrenoceptors in mouse. Physiol. Genomics (2002) 9:85-91.
23. 1A-adrenergic receptor. J. Biol. Chem. (2001) 276:13738-13743.
24. KELLUM JA, PINSKY MR: Use of vasopressor agents in critically ill patients. Curr. Opin. Crit. Care (2002) 8:236-241.
25. WANG M, LUNG MA: Adrenergic mechanisms in canine nasal venous systems. Br. J. Pharmacol. (2003) 138:145-155.
26. COOPER DW, MOWBRAY P: Can choice of vasopressor therapy affect rostral spread of spinal anaesthetic? Anesthesiology (2003) 98:1524.
27. GRASSI G: Sympathetic deactivation as a goal of non-pharmacologic and pharmacologic antihypertensive treatment: rationale and options. Curr. Hypertens. Rep. (2003) 5:277-280.
28. VAUGHAN ED Jr: Medical management of benign prostatic hyperplasia-are two drugs better than one? N. Engl. J. Med. (2003) 349:2449-2451.
29. 3H]-prazosin binding. Mol. Pharmacol. (1986) 29:321-330.
30. 3H]-5-methylurapidil. Eur. J. Pharmacol. (1989) 172:329-337.
31. 1A receptor in rat and guinea pig hippocampal membranes. Eur. J. Pharmacol. (1987) 137:293-294.
32. 1-adrenoceptor. Eur. J. Pharmacol. (1995) 272:R5-R6.
33. HIEBLE JP, BONDINELL WE, RUFFOLO RR Jr: α- and β-Adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification. J. Med. Chem. (1995) 38:3415-3444.
34. RUFFOLO RR Jr, BONDINELL WE, HIEBLE JP: α- and β-Adrenoceptors: from the gene to the clinic. 2. Structure-activity relationships and therapeutic applications. J. Med. Chem. (1995) 38:3681-3716.
35. 1-Adrenoceptor subtypes: a synopsis of their pharmacology and molecular biology. Drug Dev. Res. (1996) 39:54-107.
36. 1-adrenoceptor antagonists for the treatment of benign prostatic hyperplasia. Expert Opin. Invest. Drugs (1999) 8:2073-2094.
37. 1a-adrenergic receptor antagonists. Ann. Rep. Med. Chem. (2000) 35:221-230.
38. 1-adrenoceptor ligands. J. Med. Chem. (1991) 34:1850-1854.
39. 1-adrenoceptor subtypes. J. Med. Chem. (2003) 46:2877-2894.
40. 1A-adrenoceptor selective antagonists for the treatment of benign prostatic hyperplasia. Drugs Fut. (2001) 26:757-765.
41. 2+ channel antagonist niguldipine. J. Med. Chem. (1995) 38:1579-1581.
42. 1A-adrenergic receptor determines subtype selectivity of dihydropyridine antagonists. Biochemistry (1996) 35:14312-14317.
43. 1A-adrenergic receptor antagonist with high oral bioavailability. J. Med. Chem. (2000) 43:2775-2778.
44. 1d subtype in filling symptoms and effects of ageing on vascular expression. BJU Int. (2000) 85(Suppl.2):6-11.
45. BURNETT MD: Nitric oxide control of lower genitourinary tract functions: a review. Urology (1995) 45:1071-1083.
46. 1L adrenoceptor in tissue selectivity, Part I. J. Pharmacol. Exp. Ther. (1997) 81:1272-1283.
47. 1-antagonists. J. Med. Chem. (2003) 46:3762-3765.
48. 1a-adrenergic receptor antagonists. J. Med. Chem. (2000) 43:2183-2195.
49. 1-adrenergic receptor antagonists. Bioorg. Med. Chem. Lett. (2000) 10:1093-1096.
50. KHATUYA H, PULITO VL, JOLLIFFE LK, LI X, MURRAY WV: Novel thiophene derivatives for the treatment of benign prostatic hyperplasia. Bioorg. Med. Chem. Lett. (2002) 12:2145-2148.
51. 1D-adrenoceptor. 216th ACS National Meeting, Boston, USA (1998).
52. 1-Adrenoceptor antagonists. 6. Structural optimazation of pyriddazinone-arllpiperazines. Study of the influence on affinity and selectivity of cyclic substituents at the pyridazinone ring and alkoxy groups at the arylpiperazine moity. J. Med. Chem. (2003) 46:3555-3558.
53. 1-adrenoceptors. Il Farmaco (1995) 50:471-477.
54. 1D-receptor. Bioorg. Med. Chem Lett. (2001) 11:1119-1121.
55. 1-adrenoceptor antagonist with uroselective properties. J. Pharmacol. Exp. Ther. (2002) 300:478-486.
56. 1D-adrenoceptors, on intraurethral and arterial pressure responses in conscious dogs. J. Pharmacol. Exp. Ther. (2002) 300:487-494.
57. 1-adrenoceptor antagonists. J. Pharmacol. Exp. Ther. (2002) 300:495-504.
58. 1B-adrenoceptor antagonist. J. Med. Chem. (1996) 39:4602-4607.
59. 1b adrenergic receptor antagonist. J. Med. Chem. (1998) 41:1205-1208.
60. CAMPBELL SF, DAVEY MJ: Doxazosin, a case history. Drug Des. Deliv. (1986) 1:83-89.
61. 1-adrenoceptor antagonists. Bioorg. Med. Chem. (2003) 11:1065-1078.
62. 1-adrenoceptor antagonists. J. Med. Chem. (2003) 46:265-283.
63. 1-adrenoceptor antagonists. J. Med. Chem. (2003) 46:1504-1511.
64. 1A receptor affinity. Eur. J. Pharmacol. (2001) 433:123-127.
65. 1-adrenoceptor ligand with an enhanced in vitro and in vivo profile relative to phenylpropanolamine and midodrine. J. Med. Chem. (2002) 45:4395-4397.
66. 1-adrenoceptor and noradrenaline transporter. Nature Neurosc. (2001) 4:902-907.
67. 1-adrenoreceptor antagonism by the conopeptide P-TIA, J. Biol. Chem. (2003) 278:34451-34457.
68. 1A-adrenoceptor selective antagonists. Br J. Pharmacol. (1999) 127:252-258.
69. 1L adrenoceptor in tissue selectivity; part I. J. Pharmacol. Exp. Ther. (1997) 281:1272-1283.
70. MICHEL MC, SCHÄFERS RF, GOEPEL M: α-Blockers and lower urinary tract function: more than smooth muscle relaxation? BJU Int. (2000) 86(Suppl.2):23-30.
71. 1-adrenergic receptor subtypes in lower urinary tract symptoms. BJU Int. (2000) 86(Suppl.2 ):11-22.
72. 1-adrenoceptors. Their role in the modulation of attention and memory formation. Pharmacol Ther. (1999) 83:49-65.
73. 1-adrenoceptor subtypes in facilitation of rat spinal motoneuron activity. (1997) Eur. J. Pharmacol. 340:45-62.
74. 1B-adrenoceptors in the motor activity and spontaneous movement of mice. Neuropharmacol. (2001) 40:254-261.
75. 1b-Adrenergic receptors control locomotor and rewarding effects of psychostimulants and opiates. J. Neurosci. (2002) 22:2873-2884.